Cargando…

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study

BACKGROUND: Patients who undergo hemodialysis (HD) or kidney transplantation (KTx) previously had limited possibilities for treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals (DAA) give these patients a chance of virus eradication and safe transplantation. The aim of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tronina, Olga, Durlik, Magdalena, Orłowska, Iwona, Lorenc, Beata, Łapiński, Tadeusz W., Garlicki, Aleksander, Dybowska, Dorota, Zarębska-Michaluk, Dorota, Tudrujek-Zdunek, Magdalena, Citko, Jolanta, Janczewska, Ewa, Kaczmarczyk, Marcin, Jaroszewicz, Jerzy, Krygier, Rafał, Klapaczyński, Jakub, Dobracka, Beata, Białkowska-Warzecha, Jolanta, Piekarska, Anna, Simon, Krzysztof, Halota, Waldemar, Pawłowska, Małgorzata, Tomasiewicz, Krzysztof, Flisiak, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8079881/ https://www.ncbi.nlm.nih.gov/pubmed/33948071 http://dx.doi.org/10.20524/aog.2021.0595

Ejemplares similares

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study
por: Janczewska, Ewa, et al.
Publicado: (2021)

HCV Genotype Has No Influence on the Incidence of Diabetes—EpiTer Multicentre Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Hepatitis C Infection as a Risk Factor for Hypertension and Cardiovascular Diseases: An EpiTer Multicenter Study
por: Rajewski, Paweł, et al.
Publicado: (2022)

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Rescue Therapy after Failure of HCV Antiviral Treatment with Interferon-Free Regimens
por: Tronina, Olga, et al.
Publicado: (2023)

Prevalence of HCV genotypes in Poland – the EpiTer study
por: Flisiak, Robert, et al.
Publicado: (2016)

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Efficacy of 8- versus 12-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C patients eligible for 8-week regimen in a real-world setting
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2019)

Real-World Effectiveness and Safety of Direct-Acting Antivirals in Patients with Chronic Hepatitis C and Epilepsy: An Epi-Ter-2 Study in Poland
por: Pazgan-Simon, Monika, et al.
Publicado: (2023)

Efficacy of HCV treatment in Poland at the turn of the interferon era – the EpiTer study
por: Flisiak, Robert, et al.
Publicado: (2016)

The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study
por: Janczewska, Ewa, et al.
Publicado: (2018)

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2022)

Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
por: Flisiak, Robert, et al.
Publicado: (2023)

Five-Year Follow-Up of Cured HCV Patients under Real-World Interferon-Free Therapy
por: Flisiak, Robert, et al.
Publicado: (2021)

Searching for the optimal population for hepatitis C virus screening in Poland
por: Piekarska, Anna, et al.
Publicado: (2020)

Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6
por: Flisiak, Robert, et al.
Publicado: (2021)

Effect of comedication on ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin therapy in chronic hepatitis C – a real-world study
por: Simon, Krzysztof Adam, et al.
Publicado: (2019)

Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders
por: Dybowska, Dorota, et al.
Publicado: (2023)

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era
por: Brzdęk, Michał, et al.
Publicado: (2023)

Real-World Efficacy and Safety of an 8-Week Glecaprevir/Pibrentasvir Regimen in Children and Adolescents with Chronic Hepatitis C—Results of a Multicenter EpiTer-2 Study
por: Pawlowska, Malgorzata, et al.
Publicado: (2023)

Effectiveness of Tocilizumab with and without Dexamethasone in Patients with Severe COVID-19: A Retrospective Study
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Impact of Kidney Failure on the Severity of COVID-19
por: Zarębska-Michaluk, Dorota, et al.
Publicado: (2021)

Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2023)

Recommendations for the management of non-alcoholic fatty liver disease (NAFLD)
por: Tomasiewicz, Krzysztof, et al.
Publicado: (2018)

The Impact of IL28B Genotype and Liver Fibrosis on the Hepatic Expression of IP10, IFI27, ISG15, and MX1 and Their Association with Treatment Outcomes in Patients with Chronic Hepatitis C
por: Domagalski, Krzysztof, et al.
Publicado: (2015)

Inflammatory and thrombotic parameters associated with the COVID-19 course in Poland (SARSTer study)
por: Czupryna, Piotr, et al.
Publicado: (2022)

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study
por: Janczewska, Ewa, et al.
Publicado: (2015)

Association of IL28B Polymorphisms With the Response to Peginterferon Plus Ribavirin Combined Therapy in Polish Patients Infected With HCV Genotype 1 and 4
por: Domagalski, Krzysztof, et al.
Publicado: (2013)

Remdesivir Decreases Mortality in COVID-19 Patients with Active Malignancy
por: Jaroszewicz, Jerzy, et al.
Publicado: (2022)

Controlled Attenuation Parameter Is Associated with a Distinct Systemic Inflammatory Milieu after Clearance of HCV Infection
por: Du, Yanqin, et al.
Publicado: (2023)

The prevalence of IgE-dependent sensitizations to selected trophoallergens and airborne allergens in the population of children and adolescents of the north-eastern region of Poland
por: Kaczmarski, Maciej, et al.
Publicado: (2020)

IgE-dependent sensitization to tropho- and aeroallergens with regard to age, sex and birth season of children and adolescents living in the north-eastern region of Poland
por: Kaczmarski, Maciej, et al.
Publicado: (2021)

The frequency of IgE-dependent sensitization to food and airborne allergens in the population of children and adolescents of north-eastern Poland in 1998–2012 and its relation to the age of the studied patients
por: Kaczmarski, Maciej, et al.
Publicado: (2023)

Convalescent Plasma Transfusion for the Treatment of COVID-19—Experience from Poland: A Multicenter Study
por: Moniuszko-Malinowska, Anna, et al.
Publicado: (2020)

Recommendations for the treatment of hepatitis B in 2017
por: Flisiak, Robert, et al.
Publicado: (2017)

Liver Transplantation for a Metastatic Pancreatic Solid-Pseudopapillary Tumor (Frantz Tumor): A Case Report
por: Wójciak, Michał, et al.
Publicado: (2018)

Pregnancy after liver transplant: maternal and perinatal outcomes
por: Marzec, Izabela, et al.
Publicado: (2021)

Distribution of HBV genotypes in Poland
por: Świderska, Magdalena, et al.
Publicado: (2015)

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
por: Flisiak, Robert, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tnsbk974c0c2h0388idp34ep5j